Novartis Raises FullYear Guidance Signaling Strong Growth Prospects Stellantis Turnaround Plan Prediction Market Regulation Oura IPO Filing Among Key Investor Topics in CNBC Morning Squawk Este Lauder Shares Rise Premarket After Termination of Merger Talks with Puig CPF LIFE vs SelfInvestment The Retirement Decision Hinges on Financial Management in Old Age OpenAIs Potential IPO Could Be RecordBreaking Industry Watchers Suggest US and Iran Signal Potential Progress in Talks but Key Disputes Over Uranium and Strait of Hormuz Tolls Remain IART Q1 2026 Earnings Strong EPS Beat Drives Modest Stock Gain TDAY Q1 2026 Earnings Profitability Surprise as EPS Beats Estimates Stock Flat Nanobiotix SA NBTX Q4 2025 Earnings Wide EPS Miss Stock Edges Higher on Clinical Progress RKT Q1 2026 Earnings EPS Surpasses Expectations Despite Stock Decline KBR Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher RARE Q1 2026 Earnings WiderthanExpected Loss Highlights Cost Pressures Polyrizon Ltd PLRZ Soars Over 20 Key Levels and Potential Scenarios NeOnc Technologies Holdings NTHI Holds Near Support as Modest Decline Tests Key Level SORNW Holds Steady at 028 as Support and Resistance Levels Narrow Nuveen Municipal Value Fund NUV Holds Steady A Modest Uptick Amidst RangeBound Trading Cornerstone Strategic Investment Fund CLM Posts Modest Gains as Shares Hold Above Key Support Kathleen Kennedy Townsend Sells Cape Cod Home for 16 Million Quick Offer Highlights Luxury Demand BBAR Q4 2025 Earnings Earnings Beat Estimates Despite Stock Decline DTE Energy Junior Subordinated Debenture DTW Edges Higher in Quiet Trading AGIG Q3 2012 Earnings EPS Misses by Wide Margin Stock Rises Despite No Revenue Reported SSL Q1 2026 Earnings Modest EPS Beat Amidst Operational Discipline SAMG Q1 2026 Earnings Earnings Miss as EPS Falls Short of Estimates MBC Q1 2026 Earnings EPS Surges 69 Above Estimates Shares Jump 127 BWBBP Q1 2026 Earnings Preferred Stock EPS Slightly Misses Estimates Stock Declines Modestly iQSTEL Inc Q4 2025 Earnings EPS Misses Estimates Significantly Vistagen Therapeutics VTGN Q1 2026 Earnings Narrowing Loss Beats Estimates as Pipeline Progress Continues